Welcome to our dedicated page for Guided Thera SEC filings (Ticker: GTHP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for Guided Therapeutics, Inc. (OTCQB: GTHP), a company in the surgical and medical instrument manufacturing industry that focuses on early disease detection using patented biophotonic technology. While no specific filings are listed in the data provided here, investors typically look to SEC documents to understand a company’s risks, business description and financial condition.
Guided Therapeutics’ business context includes the development and commercialization of the LuViva® Advanced Cervical Scan, a non-invasive device for cervical disease detection at the point of care. In its public communications, the company refers readers to risk factor discussions in its Annual Report on Form 10-K and subsequent filings, where it highlights uncertainties such as the ability to commercialize products or continue as a going concern, the uncertainty of regulatory approval and dependence on licensed intellectual property.
On Stock Titan’s SEC filings page, users can review documents such as annual reports (Form 10-K), quarterly reports (Form 10-Q), current reports (Form 8-K) and registration statements when they are available from EDGAR. These filings often expand on topics mentioned in press releases, including clinical and regulatory developments, commercialization plans for LuViva, and relationships with partners and distributors.
To make these materials easier to work with, this page pairs real-time updates from EDGAR with AI-powered summaries that explain the key points of lengthy filings. Users can quickly see how Guided Therapeutics describes its business, technology, risk factors and financing arrangements without reading every page in detail. When Form 4 insider transaction reports or proxy statements are available, they can also be accessed here, with AI-generated highlights to help interpret executive and director activity in the context of GTHP’s overall disclosure record.
Guided Therapeutics, Inc. files its annual report outlining a business built around the LuViva® Advanced Cervical Scan, a non-invasive cervical cancer detection device using biophotonic technology. The company targets large screening markets in developing countries and triage use in developed markets, but remains pre-revenue with only limited product sales.
Management discloses substantial doubt about its ability to continue as a going concern, citing an accumulated deficit of $157.1 million, total liabilities of $7.3 million and $1.13 million of senior unsecured convertible debentures in default. The business depends on securing new debt or equity financing and on obtaining key regulatory approvals, including U.S. FDA premarket approval and China NMPA clearance for LuViva.
GUIDED THERAPEUTICS INC director and 10% owner John E. Imhoff reported several stock-accretive transactions. He converted portions of a September 25, 2025 convertible promissory note into 195,460, 312,720 and 156,086 shares of common stock at a conversion price of $0.07 per share, turning principal and accrued interest into equity.
Imhoff also converted 100 shares of Series E preferred stock with a stated value of $1,000 and a $0.25 conversion price into 400,000 common shares, and received additional common shares for accrued Series E dividends. During February 2026, he exchanged 500,000 warrants with a $0.50 exercise price for 500,000 warrants at $0.20, then exercised the new warrants for 500,000 common shares upon payment of $100,000, while extending the expiration of 500,000 warrants at $0.65 by one year. Following the latest reported transactions, he directly holds 21,053,099 shares of common stock.
Guided Therapeutics, Inc. completed a warrant exchange that issued 4,825,000 shares of common stock and generated $980,000 in cash proceeds from warrant exercises. Holders tendered 4,825,000 Eligible Warrant Shares, about 22.7% of the warrants issued in the September 1, 2022 private offering.
The company exchanged each tendered warrant share for 1 restricted common share and cancelled those warrants, while extending the expiration of remaining unexercised Eligible Warrants by one year for participating holders. Shares outstanding rose from 86,691,976 to 91,516,976 as of March 2, 2026, and 16,398,080 Eligible Warrants remain outstanding with expirations in 2026 and 2027.
Guided Therapeutics Inc. director James Michael C reported warrant exchanges and an exercise involving the company’s common stock. In February 2026, he exchanged 100,000 warrants with a $0.65 exercise price for 100,000 new warrants with a $0.25 exercise price, then exercised the new warrants for $25,000, receiving 100,000 common shares. As part of the same agreement, the expiration date of separate 4‑year warrants for 100,000 shares with a $0.50 exercise price was extended to September 1, 2027. Following these transactions, he directly held 653,495 common shares and 52,778 warrants.
Guided Therapeutics (GTHP) reported Q3 2025 results. Sales of devices and disposables were $60 thousand with gross profit of $35 thousand, while operating expenses reached $520 thousand. The company posted a net loss of $742 thousand for the quarter and $1.978 million for the nine months.
Liquidity remains tight with cash and cash equivalents of $87 thousand and total assets of $903 thousand against total liabilities of $6.549 million. Stockholders’ deficit was $5.646 million. The company disclosed a going concern uncertainty, citing a working capital deficit of about $5.7 million and ongoing operating losses.
To fund operations year-to-date, GTHP raised $260 thousand via private placements and $623 thousand in notes (including related parties), and issued 18.47 million shares from conversions, financing, and interest/dividends paid in stock. Deferred revenue stood at $689 thousand, short-term convertible debt in default was $1.130 million, and 83,599,156 common shares were outstanding as of November 10, 2025.